Research shows that blocking a protein called TMEM141 can reverse fatty liver disease and liver scarring in mice, according to a 2026 Nature Communications study. Scientists found that a new drug targeting TMEM141 reduced liver fat, inflammation, and scarring in mice with established disease, suggesting this protein could be a promising treatment target for millions of people with fatty liver disease.
Scientists have discovered that a protein called TMEM141 plays a major role in fatty liver disease, a condition affecting millions of people worldwide. According to Gram Research analysis, when researchers blocked this protein in mice, it reduced liver damage and scarring caused by unhealthy diets. The study, published in Nature Communications in 2026, suggests that a new drug targeting TMEM141 could help reverse fatty liver disease and prevent serious complications. This discovery opens a promising new path for treating a disease that currently has limited treatment options.
Key Statistics
A 2026 Nature Communications study found that genetic removal of TMEM141 from liver cells protected mice against fatty liver disease and scarring, even when fed a high-fat, high-cholesterol, high-fructose diet.
According to Gram Research analysis of the 2026 study, a new drug blocking TMEM141 (GalNAc-siTmem141) significantly reversed existing fatty liver disease and liver scarring in mice, demonstrating the disease may be reversible with targeted treatment.
The 2026 research showed that TMEM141 controls free radical production in mitochondria, and blocking this protein activates a protective protein called HNF4α that prevents liver damage and scarring.
The Quick Take
- What they studied: Whether blocking a protein called TMEM141 could reduce fatty liver disease and liver scarring in mice fed unhealthy diets
- Who participated: Laboratory mice with fatty liver disease caused by high-fat, high-cholesterol, high-fructose diets, plus liver tissue samples from patients with fatty liver disease
- Key finding: Blocking TMEM141 significantly reduced liver fat buildup, inflammation, and scarring in mice. A new drug that blocks this protein also reversed existing liver damage.
- What it means for you: This research suggests a potential new treatment for fatty liver disease, though human clinical trials are still needed to confirm safety and effectiveness
The Research Details
Researchers used multiple approaches to study TMEM141. First, they examined liver tissue from patients with fatty liver disease and found that TMEM141 levels were abnormally low. Then they created mice with genetic changes to remove or increase TMEM141 and fed them unhealthy diets to see how the protein affected liver disease development. Finally, they tested a new drug designed to block TMEM141 in mice with existing liver damage to see if it could reverse the disease.
The scientists discovered that TMEM141 sits inside mitochondria, which are the energy factories of cells. This protein interacts with a part of the mitochondria called complex I, which controls how much harmful molecules called free radicals (ROS) the cell produces. By blocking TMEM141, they reduced free radical production and activated a protective protein called HNF4α.
This multi-layered approach—combining genetic studies, cellular analysis, and drug testing—allowed researchers to understand both how TMEM141 causes liver disease and whether blocking it could be an effective treatment strategy.
This research matters because current treatments for fatty liver disease are limited. By identifying TMEM141 as a key player in the disease, scientists have found a new target for drug development. The fact that blocking this protein not only prevented disease but also reversed existing liver damage in mice is particularly exciting, as it suggests the disease may be reversible with the right treatment.
This study was published in Nature Communications, a highly respected scientific journal. The researchers used multiple complementary approaches (genetic, molecular, and pharmacological) to confirm their findings, which strengthens confidence in the results. They also tested their findings in both disease prevention and reversal scenarios. However, all experiments were conducted in mice and cell cultures, so human clinical trials are needed before this treatment can be used in patients.
What the Results Show
When researchers removed the TMEM141 gene from liver cells in mice, the animals were protected against developing fatty liver disease even when fed an unhealthy diet high in fat, cholesterol, and fructose. Mice with TMEM141 removed showed significantly less liver fat accumulation, reduced inflammation, and less liver scarring (fibrosis) compared to normal mice on the same diet.
The protective effect worked through a specific mechanism: blocking TMEM141 reduced the production of harmful free radicals inside mitochondria, which then activated a protective protein called HNF4α. This protein acts like a repair system for the liver, helping to prevent damage and scarring.
Most importantly, when researchers tested a new drug (GalNAc-siTmem141) that blocks TMEM141 in mice that already had established fatty liver disease and scarring, the drug reversed both conditions. Liver fat decreased, inflammation improved, and scarring was reduced. This suggests the disease is not permanent and can be reversed with the right treatment.
In contrast, when researchers increased TMEM141 levels in mice, it made fatty liver disease worse, confirming that this protein is harmful in the context of liver disease.
The research revealed that TMEM141 levels are controlled by a molecule called microRNA-149, which is increased in patients with fatty liver disease. This explains why TMEM141 is naturally reduced in people with the disease. The study also showed that HNF4α is essential for the protective effects of blocking TMEM141—when researchers removed HNF4α, blocking TMEM141 no longer protected against liver disease, demonstrating that this protein is a critical part of the protective pathway.
Fatty liver disease has been linked to obesity and unhealthy diets for years, but scientists have struggled to find effective treatments. Previous research identified various factors that contribute to the disease, but TMEM141 is a newly discovered player in this process. This study is the first to identify TMEM141’s role in liver disease and to show that blocking it can reverse existing damage. The finding that a single protein can be targeted to reverse the disease represents a significant advance in understanding how to treat this condition.
All experiments were performed in mice and laboratory cell cultures, not in humans. While mouse studies are valuable for understanding disease mechanisms, results don’t always translate directly to humans. The study did not include human clinical trials, so we don’t yet know if blocking TMEM141 is safe or effective in patients. Additionally, the study focused on one specific type of unhealthy diet; it’s unclear whether the findings apply to fatty liver disease caused by other factors like alcohol consumption or certain medications. Finally, the long-term effects of blocking TMEM141 were not studied, so potential side effects from long-term treatment are unknown.
The Bottom Line
Based on this research, blocking TMEM141 appears to be a promising strategy for treating fatty liver disease and liver scarring. However, these findings are preliminary and based on animal studies. People with fatty liver disease should continue following current medical advice: maintain a healthy weight, eat a balanced diet low in processed foods and added sugars, limit alcohol, and work with their healthcare provider. If TMEM141-blocking drugs enter human clinical trials, they may become an important treatment option in the future.
This research is most relevant to people with fatty liver disease (MASLD/MASH), their doctors, and pharmaceutical companies developing new treatments. People with obesity, type 2 diabetes, or metabolic syndrome should be aware of this research since they have higher risk for fatty liver disease. Healthcare providers treating liver disease should monitor developments in TMEM141-targeting drugs. However, this treatment is not yet available for human use, so current patients cannot benefit immediately.
In mice, blocking TMEM141 showed benefits within weeks to months. However, human clinical trials typically take 3-7 years to complete. If this drug moves forward in development, it could potentially be available to patients within 5-10 years, assuming it proves safe and effective in human studies.
Frequently Asked Questions
What is TMEM141 and why does it cause fatty liver disease?
TMEM141 is a protein that sits inside mitochondria (the energy factories of liver cells) and controls the production of harmful free radicals. High levels of TMEM141 increase free radical damage, leading to fat accumulation, inflammation, and scarring in the liver. Blocking this protein reduces damage and activates protective mechanisms.
Can this new TMEM141 drug treat fatty liver disease in humans right now?
Not yet. The drug has only been tested in mice and laboratory cells. Human clinical trials are needed to confirm it’s safe and effective in people. If development continues successfully, this treatment could potentially become available within 5-10 years.
Is fatty liver disease reversible with this treatment?
In mice, blocking TMEM141 reversed both fatty liver disease and liver scarring that had already developed. This suggests the disease may be reversible, but human studies are needed to confirm this. Current lifestyle changes (diet, exercise, weight loss) can also help reverse early-stage fatty liver disease.
Who should be most interested in this research?
People with fatty liver disease, those with obesity or type 2 diabetes (who have higher risk), and their healthcare providers should follow this research. The drug is not yet available, but staying informed helps patients discuss potential future treatments with their doctors.
What should I do now if I have fatty liver disease?
Continue following current medical advice: maintain a healthy weight, eat a balanced diet low in processed foods and added sugars, exercise regularly, limit alcohol, and work with your healthcare provider. Monitor for new treatments like TMEM141-blocking drugs as they advance through clinical trials.
Want to Apply This Research?
- Track liver health markers: record any fatigue, abdominal bloating, or right upper abdominal discomfort weekly. If using the app with a healthcare provider, log any liver function test results (ALT, AST, GGT levels) when available to monitor disease progression or improvement.
- Use the app to set and track dietary goals that reduce liver disease risk: limit added sugars to under 25g daily, reduce saturated fat intake, eliminate sugary drinks, and maintain a healthy weight. Set reminders for regular exercise (150 minutes weekly) and alcohol avoidance, both critical for liver health.
- Create a long-term liver health dashboard tracking: monthly weight changes, quarterly dietary adherence scores, and any available lab results from healthcare visits. Set alerts to remind users to schedule annual liver function tests and to discuss new treatment options (like TMEM141-targeting drugs when available) with their doctor.
This article summarizes research findings and is for educational purposes only. It does not constitute medical advice. TMEM141-blocking drugs are not yet approved for human use and are still in research stages. If you have fatty liver disease or concerns about your liver health, consult with a qualified healthcare provider before making any changes to your treatment plan. Do not delay or avoid seeking professional medical care based on this information.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.